SHR 3167
Alternative Names: SHR-3167Latest Information Update: 30 Aug 2023
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 18 Aug 2023 Preclinical trials in Type 2 diabetes mellitus in China (SC) (Jiangsu Hengrui Medicine Co. pipeline, August 2023) (NCT05996380)
- 18 Aug 2023 Jiangsu Hengrui Medicine Co. plans a phase I trial for Type 2 diabetes mellitus in August 2023 (SC, Injection) (NCT05996380)
- 09 Jun 2023 Phase-I clinical trials in Type 2 diabetes mellitus in China (SC) (NCT05996380)